Aberrant activation of β1 and β2 integrins on leukocytes in JAK2-V617F mutated disease (A20)

• Subject Area: Hematology, Oncology
• Term: from 2010 to 2021
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 97850925

A20 investigates the activation of integrins on leukocytes in JAK2-V617F-positive chronic myeloproliferative neoplasia (CMN). JAK2-mutated CMN is characterized by clonal proliferation of myeloid cells and a striking inflammatory syndrome. In the previous funding period, we found that JAK2-V617F aberrantly activates β1 and β2 integrins (VLA4 and LFA1) on leukocytes in CMN and identified the molecular mechanisms involved. Using the Vav1-Cre x JAK2+/V617F knock-in mouse model established in our laboratory, we aim to dissect the contribution of aberrant integrin activation for the JAK2-V617F- induced cytokine dysregulation, splenomegaly and pro-thrombotic state.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 854: Molecular Organisation of Cellular Communications within the Immune System
• Applicant Institution: Otto-von-Guericke-Universität Magdeburg
• Project Heads: Professor Dr. Thomas Fischer; Professor Dr. Florian Heidel, until 11/2015